Apolipoprotein E dose-dependent modulation of β-amyloid deposition in a transgenic mouse model of Alzheimer's disease

Author: DeMattos, Ronald

Source: Journal of Molecular Neuroscience, Volume 23, Number 3, October 2004 , pp. 255-262(8)

Publisher: Humana Press

Buy & download fulltext article:

OR

Price: $42.00 plus tax (Refund Policy)

Abstract:

Susceptibility to the development of Alzheimer's disease (AD) is increased for individuals harboring one or more apolipoprotein E4 (apoE4) alleles. Even though several isoform-specific effects of apoE have been identified, the relationship between biochemical function and risk factor assessment remains unknown. Our previous studies have demonstrated that there is an equilibrium between cerebral spinal fluid (CSF) and plasma β-amyloid (Aβ) and that amyloid plaques can modify this equilibrium. Trafficking of soluble central nervous system (CNS) Aβ is a very dynamic system that almost certainly is modulated by Aβ-binding proteins. Altered trafficking of the Aβ peptide might have a dramatic consequence as to whether the peptide is metabolized or begins to deposit within the brain. To gain a better understanding of the molecular mechanisms by which apoE influences AD pathogenesis and/or Aβ trafficking, we developed PDAPP transgenic mice that express different levels of human apoE3. Analysis of the soluble CNS pools of Aβ in young mice showed an apoE3 dose-dependent decrease in Aβ levels (E3−/−>E3−/−>E3+/+). In addition to the dose-dependent effects on soluble Aβ, by 15 mo of age there were highly significant differences in the amount of deposited Aβ between the genotypes (E3−/−>E3−/−>E3+/+). These data indicate that apoE3 provides a dose-dependent protective effect against Aβ deposition. This study suggests that increasing human apoE levels in brain might be a possible therapeutic target for preventing AD.

Keywords: Apolipoprotein E; Alzheimer's disease; amyloid; transgenic; cerebralspinal fluid

Document Type: Research article

DOI: http://dx.doi.org/10.1385/JMN:23:3:255

Affiliations: 1: Neuroscience Discovery Research, Eli Lilly and Co., Lilly Research Laboratories, 46285, Indianapolis, IN, Email: demattos_ronald_bradley@lilly.com

Publication date: 2004-10-01

Related content

Tools

Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content

Text size:

A | A | A | A
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages. print icon Print this page